Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.
about
Molecular and cytogenetic characterization of expanded B-cell clones from multiclonal versus monoclonal B-cell chronic lymphoproliferative disordersWhole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphomaGenetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin.Lower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal center-independent B cell response.Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical featuresTreatment of splenic marginal zone lymphoma: should splenectomy be abandoned?Splenic marginal zone lymphoma: disease features and management.Splenic marginal-zone lymphoma: ontogeny and genetics.Tissue proteomics of splenic marginal zone lymphoma.Restricted, canonical, stereotyped and convergent immunoglobulin responses.Genetic landscape and deregulated pathways in B-cell lymphoid malignancies.Antigen receptor stereotypy in chronic lymphocytic leukemia.Mantle cell lymphoma cell lines show no evident immunoglobulin heavy chain stereotypy but frequent light chain stereotypy.Early stages in the ontogeny of small B-cell lymphomas: genetics and microenvironment.Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma.Immunoglobulin gene repertoire in chronic lymphocytic leukemia: insight into antigen selection and microenvironmental interactions.Expression of immunoglobulin receptors with distinctive features indicating antigen selection by marginal zone B cells from human spleen.A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders.The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma.Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases.Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region.Chronic Lymphocytic Leukemia Patient Clustering Based on Somatic Hypermutation (SHM) Analysis.Langerhans cell sarcoma following marginal zone lymphoma: expanding the knowledge on mature B cell plasticity.A gene is known by the company it keeps: enrichment of TNFAIP3 gene aberrations in MALT lymphomas expressing IGHV4-34 antigen receptors.KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies.Persistent polyclonal B-cell lymphocytosis: extensively proliferated CD27+IgM+IgD+ memory B cells with a distinctive immunophenotype.IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma.Recent advances in understanding the biology of marginal zone lymphoma.Selection of antigen receptors in splenic marginal-zone lymphoma: further support from the analysis of the immunoglobulin light-chain gene repertoire
P2860
Q28385156-4FFE5731-2892-4244-854D-7174F1F7BF19Q28537689-4B7875DE-B65E-4ECE-9211-139072D7E7EFQ35812737-0F4B6B18-53AE-4663-B09D-DA6090DFD983Q36193517-38032222-8433-481F-ADFA-F1583D77ED74Q36413119-940F2FC7-9D5D-4392-91FB-1A5E223B0718Q36616521-29D77864-690E-4469-A9DD-6568C4E140C8Q36779686-0DEEAF77-F44B-4771-8E49-4978E786FBF6Q37149519-EE37797C-3F7E-45D0-87C1-37F5E29A49C6Q38139569-ADF27A93-97A2-4A3D-B2E5-7F99B41F57C0Q38156238-8A5411FF-5A5F-4820-BA63-D07B39059341Q38209575-ED8CF15E-60E3-4CA5-AC9C-F94B9062BC5BQ38413335-59654DAA-5EC3-4E2E-8A17-36F1B15479C6Q38551067-C843A6B8-96F8-42A1-B2BF-34C7C09529FDQ38669131-1998FEBA-678B-48C2-9843-8374855AC66EQ38998146-C80BE7B6-494E-42B6-B84F-093995E529C4Q39225258-2418838F-5DAB-4769-AC4C-1A9AD8F90D10Q39230986-DFF0ECBE-849A-43E6-902B-EAE01BEA3C81Q39406673-11A01364-1745-459F-AB91-FB23DE986B79Q40145663-36957E78-4289-48C6-8F40-197E3CFC1F61Q42323395-25371732-F26C-40FB-88C8-99CE47306342Q42610409-5BCF5774-411E-472E-8B8B-ACB44FDFDEC0Q42923403-1B8A9866-E203-421F-9262-839F880AC821Q43854217-0A917D4D-A3C8-43B4-AB48-551B1AF43B10Q44133528-8EE539E9-AED5-4973-AC67-6D754000005AQ47123855-58E55C39-5EE9-4199-9D9C-43663D061FA9Q47607917-0CB03212-52FA-4F7D-AD61-F94E900B2447Q47657605-699B76D7-266F-4C3D-A03F-CDE5BECED011Q47823277-199865AD-8BE5-4E93-A72B-88DF1131CA7AQ48250566-4D631381-41CB-4BF1-A783-4963AD710484Q50236578-E9DB15FB-138A-475B-A02B-D40077424902Q50860272-16D31590-70F2-4234-8486-33B8800B4F13Q53147192-90E3765A-61A9-4D77-83F9-6C444924930BQ55006191-A6361024-A5D3-478C-A604-AC185107E80DQ55106506-FA9E555A-7A79-41F9-B5A3-2B62F6613E54Q58041565-778AB01B-CCC4-4310-AEA2-ED6917CA57E8
P2860
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Over 30% of patients with sple ...... ene: ontogenetic implications.
@en
Over 30% of patients with sple ...... ene: ontogenetic implications.
@nl
type
label
Over 30% of patients with sple ...... ene: ontogenetic implications.
@en
Over 30% of patients with sple ...... ene: ontogenetic implications.
@nl
prefLabel
Over 30% of patients with sple ...... ene: ontogenetic implications.
@en
Over 30% of patients with sple ...... ene: ontogenetic implications.
@nl
P2093
P2860
P50
P356
P1433
P1476
Over 30% of patients with sple ...... ene: ontogenetic implications.
@en
P2093
A Hadzidimitriou
A Traverse-Glehen
A Tsaftaris
D Gonzalez
D S Bosler
P2860
P2888
P304
P356
10.1038/LEU.2012.3
P577
2012-01-06T00:00:00Z